Viruses are responsible for many of the adaptive mutations in the human genome.
A long-standing quest in evolutionary biology has been to identify the mechanisms that cause genomes to change and diversify over time. One celebrated theory, the neutral theory, argues that the vast majority of mutations found in genomes are of no consequence, and that mutations persist entirely by random chance (Kimura, 1983). Alternatively, mutations may persist because they are adaptive; that is, the organism is better off having the mutation than not. Now, in eLife, David Enard, Le Cai, Carina Gwennap and Dmitri Petrov from Stanford University argue that viruses are one of the major drivers of adaptive mutations in the human genome and in mammalian genomes in general (Enard et al., 2016).
Enard et al. examined patterns of molecular evolution in human proteins, comparing the patterns in proteins that interact with viruses to those that do not. How do we know which human proteins interact with viruses? Since this information is not readily available, Enard et al. had to manually search the literature and read thousands of articles to build their data set. They started out with a list of 9,861 human proteins and then searched for all articles that mentioned one of the proteins as well as the word “virus.” Each article was then examined to determine whether it established a physical interaction between the human protein and either a viral protein, viral RNA or viral DNA. This procedure yielded a final list of 1,256 proteins that physically interact with viruses. The remaining proteins in the list were used as a control group, serving as point of comparison.
To assess the extent of adaptation in these proteins, Enard et al. used a test that compares patterns of mutations in the DNA sequences that encode the proteins (McDonald and Kreitman, 1991). This test separates mutations into four different types. First, it defines substitutions as those shared by all individuals in a population, and polymorphisms as those only present in some individuals. Furthermore, mutations can occur at “functional” sites, where they can modify the protein that gets expressed, or at “neutral” sites, where they have no effect on the final protein. Under the neutral theory, we expect the ratio of functional versus neutral mutations to be the same whether we are considering substitutions or polymorphisms (Figure 1A). Conversely, if some functional mutations are adaptive and result in increased fitness, then natural selection will have acted to drive an increase in the frequency of functional mutations until they are shared by all individuals. In this case, the ratio of functional versus neutral mutations will be greater for substitutions than it will be for polymorphisms (Figure 1B). More importantly for the study by Enard et al., the two ratios can also be used to estimate the fraction of substitutions driven by adaptation (Smith and Eyre-Walker, 2002).
Enard et al. find that at least 30% of the adaptive mutations that have accumulated in human genes seem to have arisen because they offer protection against viral infection. This conclusion is based on the fact that more adaptive substitutions were found in the subset of proteins that interact with viruses than in the control set of proteins that do not. The fact that so much human evolution has been focused on proteins that interact with viruses affirms what we already knew: viruses have historically been one of our biggest causes of death and disease, if not the biggest cause. They, not lions, tigers or bears, sit masterfully above us on the food chain of life, occupying a role as alpha predators who prey on everything and are preyed upon by nothing.
One seemingly puzzling result from the study is that the human proteins that interact with viruses are more evolutionarily conserved than other proteins, yet also experience more adaptive evolution. However, this can be explained by considering where the adaptive mutations occur. Viruses may evolve to interact with the conserved and essential proteins of their hosts because targeting those proteins makes it easier for the viruses to infect all individuals within a species. This may also help the viruses to infect individuals of a new species. But unfortunately for the viruses, interacting with a host protein may promote adaptive mutations at the virus-binding surface of the protein, eventually preventing the viral interaction. This selection pressure creates a hotspot of adaptive evolution in a protein that is otherwise highly conserved.
The work by Enard et al. is conservative; it likely underestimates the total amount of selection due to viruses. As the authors point out, their list of virus-interacting proteins is only a subset of the actual virus-interacting proteins encoded by the human genome. We typically only know that a protein interacts with a virus if the virus causes a significant disease burden and is well-studied, such as HIV or influenza virus. There are, however, many other unknown viruses that we encounter every day through processes such as eating and breathing. An extensive network of proteins protects us from these viruses, but the proteins in this network are difficult to identify because they act silently, protecting us so successfully that no disease results. New human viruses such as Ebola, Zika and MERS arise when one of these environmental viruses evolves to circumvent this invisible shield. In this way, diverse human proteins are engaged in a silent battle with viruses every single day.
© 2016, Wilke et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Downloads (link to download the article as PDF)
Download citations (links to download the citations from this article in formats compatible with various reference manager tools)
Open citations (links to open the citations from this article in various online reference manager services)
We analyze properties of experimental microbial time series, from plankton and the human microbiome, and investigate whether stochastic generalized Lotka-Volterra models could reproduce those properties. We show that this is the case when the noise term is large and a linear function of the species abundance, while the strength of the self-interactions varies over multiple orders of magnitude. We stress the fact that all the observed stochastic properties can be obtained from a logistic model, that is, without interactions, even the niche character of the experimental time series. Linear noise is associated with growth rate stochasticity, which is related to changes in the environment. This suggests that fluctuations in the sparsely sampled experimental time series may be caused by extrinsic sources.
Neither the disease mechanism nor treatments for COVID-19 are currently known. Here, we present a novel molecular mechanism for COVID-19 that provides therapeutic intervention points that can be addressed with existing FDA-approved pharmaceuticals. The entry point for the virus is ACE2, which is a component of the counteracting hypotensive axis of RAS. Bradykinin is a potent part of the vasopressor system that induces hypotension and vasodilation and is degraded by ACE and enhanced by the angiotensin1-9 produced by ACE2. Here, we perform a new analysis on gene expression data from cells in bronchoalveolar lavage fluid (BALF) from COVID-19 patients that were used to sequence the virus. Comparison with BALF from controls identifies a critical imbalance in RAS represented by decreased expression of ACE in combination with increases in ACE2, renin, angiotensin, key RAS receptors, kinogen and many kallikrein enzymes that activate it, and both bradykinin receptors. This very atypical pattern of the RAS is predicted to elevate bradykinin levels in multiple tissues and systems that will likely cause increases in vascular dilation, vascular permeability and hypotension. These bradykinin-driven outcomes explain many of the symptoms being observed in COVID-19.